On Tuesday, Qiagen received a positive adjustment to its Relative Strength (RS) Rating, from 64 to 74.
IBD's proprietary rating tracks price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research shows that the best-performing stocks often have an 80 or higher RS Rating as they begin their largest climbs. See if Qiagen can continue to rebound and clear that threshold.
Can You Really Time The Stock Market?
Qiagen is building a flat base with a 47.44 entry. See if it can break out in volume at least 40% higher than normal.
In terms of top and bottom line numbers, Qiagen has posted rising EPS growth in each of the last two reports. Top line growth has also risen during the same period. Qiagen is expected to release its next quarterly numbers on or around Feb. 11.
Qiagen holds the No. 22 rank among its peers in the Medical-Products industry group. Globus Medical, Boston Scientific and Insulet are among the top 5 highly rated stocks within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
